Truist analyst Robyn Karnauskas lowered the firm’s price target on Pfizer (PFE) to $32 from $36 and keeps a Buy rating on the shares. The firm is reducing its FY25 EPS view by 9c to $2.97 given competitive pressures and Inflation Reduction Act impact across multiple aspects of the company’s portfolio including Vyndaqel, Xeljanz, Eliquis, and the vaccine portfolio, the analyst tells investors in a research note. Truist adds however that it sees Pfizer’s continued launch execution and growing oncology presence to “right the ship and return to growth”.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Trump Slams “Horrible Middlemen” and Sends CVS, UNH, & CI Stocks Tumbling
- Pfizer price target raised to $28 from $27 at Wells Fargo
- Pfizer’s 2025 guidance positions company for EPS expansion, says BMO
- Barclays fact-checked Trump comments on pharmacy benefit managers
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz